Frontlight ResearchEarly access
Active, not recruitingNo phase
Postoperative Thrombosis Prevention in Patients With CD
Key facts
- Who runs it
- Huashan Hospital
- Where
- China7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 206 people, planned
- Started
- 1 Dec 2020
- Ended
- 1 Jul 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- LMWH/Rivaroxaban
- IPC
- Record updated
- 2 July 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Cushing\'s disease diagnosed and treated with transsphenoid surgery at study centers
Who cannot take part
- History of VTE before surgery or within 24 hours post-surgery
- Major bleeding events
- History of stroke
- High risk of bleeding due to clotting abnormalities
- Presence of other malignant diseases
- Severe mental or neurological disorders
- Any other condition that researchers deem inappropriate for study participation
- Contraindications to rivaroxaban (e.g., renal dysfunction with eGFR \< 50 mL/min)
- Acute bacterial endocarditis
- Thrombocytopenia
- Active gastrointestinal ulcers
- Participation in other clinical trials within the last three months
- Presence of intracranial vascular abnormalities
- Contraindications to mechanical prophylactic anticoagulation
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients with Cushing disease was randomized to 2 groups. After surgery, the patients were managed with mechanical prevention or mechanical prevention plus anticoagulant drugs(LMWH followed by rivaroxaban), VTE was observed 24h, 5day, 4weeks and 12weeks after surgery.Bleeding events were also recorded.
The 2 groups in the trial
- mechanical preventionOther group
patients were managed with IPC
Treatment: IPC
- mechanical plus anticoagulant drugs preventionOther group
patients were managed with IPC, and LMWH was added 24h after surgery and followed by rivaroxaban 5 days after surgery
Treatment: LMWH/Rivaroxaban and IPC
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter, Randomized Controlled Study of Postoperative Initiation of Thromboprophylaxis in Patients With Cushing's Disease
- Publications
- Record updated
- 2 July 2025